Sigachi Industries
39.06
-0.70(-1.76%)
Market Cap₹1,519.30 Cr
PE Ratio21.85
IndustryHealthcare
Company Performance:
1D-1.76%
1M-30.42%
6M-14.83%
1Y-40.77%
5Y-34.74%
View Company Insightsright
Latest news about Sigachi Industries
Sigachi Industries Reports Q1 Results Amid Tragic Fire Incident 23 hours ago Yesterday
Sigachi Industries Ltd. reported mixed Q1 results, with revenue up 33.99% to ₹1,282.00 crore, but a net loss of ₹1,010.00 crore due to a ₹1,210.00 crore exceptional item related to a fire incident. The June 30 fire at their Hyderabad plant resulted in 46 fatalities and 28 injuries. Operations at the affected unit are halted for 180 days, with an estimated ₹60.00 crore revenue loss. The company is reallocating production, focusing on safety, and continuing strategic initiatives including capacity expansions and API growth.
Sigachi Industries Reports Q1 Loss Amid Tragic Fire Incident at Hyderabad Plant 1 day ago Yesterday
Sigachi Industries Disburses ₹5.80 Crore in Interim Compensation Following Pashamylaram Unit Incident 3 days ago
Sigachi Industries: Telangana Plant Explosion Death Toll Climbs to 46 8 days ago
Sigachi Industries Shares Plunge 11% Amid Fatal Fire Aftermath Jul 02, 2025
More news about Sigachi Industries
01Jul 25
Sigachi Industries: Telangana CM Announces Rs 1 Crore Compensation for Plant Explosion Victims
An explosion at Sigachi Industries' pharmaceutical plant in Telangana has resulted in 36 fatalities. Chief Minister Revanth Reddy has announced compensation of Rs 1.00 crore for each deceased victim's family. Seriously injured individuals will receive Rs 10.00 lakh, while others injured will get Rs 5.00 lakh. The government has promised immediate relief funds. Expectations are that Sigachi Industries will also contribute to compensation efforts. The incident may have significant implications for the company's operations and industry standing.
30Jun 25
Fire at Sigachi Industries' Hyderabad Plant Halts Operations for 90 Days
Sigachi Industries has suspended operations at its Hyderabad manufacturing facility for an estimated 90 days following a fire incident. The affected plant contributes 6,000 MTPA to the company's total production capacity of 21,700 MTPA. This shutdown may lead to production shortfalls, supply chain disruptions, and potential financial impacts for the quarter.
13Jun 25
Sigachi Industries Secures Approval for New API and Specialty Chemicals Plant
Sigachi Industries has received Terms of Reference (ToR) approval for a new manufacturing plant in Orvakal, Andhra Pradesh, focused on Active Pharmaceutical Ingredients (APIs) and specialty chemicals. This approval is a key step in the company's expansion strategy, potentially enhancing its market position and production capabilities. The project aligns with environmental regulations, suggesting a commitment to sustainable growth. Specific details about investment, capacity, and timelines are yet to be disclosed.
30May 25
Sigachi Industries Reports Mixed Q4 Results: EBITDA Soars, Net Profit Dips
Sigachi Industries' Q4 financial results show significant growth in EBITDA to ₹286.00 million, up from ₹163.00 million year-over-year. EBITDA margin improved to 22.27%, a 6.59 percentage point increase. Revenue grew by 23.08% to ₹1.28 billion. However, consolidated net profit declined 11.33% year-over-year to ₹133.00 million, though it increased quarter-over-quarter.
07May 25
Sigachi Industries Secures European Certification for Metformin Hydrochloride
Sigachi Industries has obtained a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Metformin Hydrochloride product. This certification validates the quality and safety standards of the product, potentially enhancing the company's access to the European pharmaceutical market. The CEP is expected to provide Sigachi Industries with a competitive advantage and serve as a quality assurance for European regulators and customers.
28Apr 25
Sigachi Industries' Subsidiary Inks MoU with Respilon for Cutting-Edge Nanofiber Drug Delivery Technology
Sigachi Industries' subsidiary, Sigachi MENA FZCO, has signed an MoU with Czech nanotechnology firm Respilon Group to develop and commercialize drug delivery solutions using NUENEX® nanofiber technology. The partnership focuses on creating Invisible Patch and Powder-based pharmaceutical delivery formats, aiming to revolutionize patient experience and improve therapeutic outcomes through non-invasive, precision drug delivery methods.
17Apr 25
Sigachi Industries Secures Environmental Clearance for Dahej 2 SEZ Facility, Paving Way for Expansion
Sigachi Industries Limited has obtained environmental clearance for a new manufacturing facility in Dahej 2 Special Economic Zone, Gujarat. The facility will have a production capacity of 3,120.00 MT/month, focusing on cellulose and starch-based specialized excipients. This strategic move aims to enhance export growth and global competitiveness in pharmaceutical, nutraceutical, and food-grade applications. The environmental clearance, granted on April 16, 2025, allows the company to proceed with site development and execution.
01Apr 25
Sigachi Industries' Stock Climbs 3.33% Amid Promoter Share Pledge and R&D Investment Plans
Sigachi Industries' stock price increased by 3.33% to ₹36.30 on Tuesday, despite overall weak market conditions. This rise occurred despite a recent share pledge by promoter Dharani Devi Chidambaranatham of 9,10,000 shares (0.23% equity). The company announced plans to invest $1 million in a new R&D center in Hyderabad, potentially boosting investor confidence in its growth strategy.
13Mar 25
Sigachi Industries Partners with Indian Navy for Health Initiative in Visakhapatnam
Sigachi Industries Limited has signed an MoU with INS Kalinga of the Indian Navy to launch an eight-month community fitness program in Visakhapatnam. The 'Vizag Navy Marathon Promo cum Conditioning Programme' will run from March to October 2025, featuring monthly events on the second Sunday. This partnership aims to promote health, wellness, and community engagement in the coastal city.
Sigachi Industries
39.06
-0.70
(-1.76%)
1 Year Returns:-40.77%
Industry Peers
Sun Pharmaceutical
1,699.00
(+0.41%)
Divis Laboratories
6,616.50
(-0.03%)
Cipla
1,532.50
(+3.00%)
Torrent Pharmaceuticals
3,603.80
(+2.38%)
Mankind Pharma
2,603.40
(+0.54%)
Dr Reddys Laboratories
1,277.90
(+0.98%)
Zydus Life Science
976.40
(+0.53%)
Lupin
1,951.00
(+0.49%)
Abbott
33,780.00
(-2.31%)
Aurobindo Pharma
1,122.80
(+0.78%)